Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-PCSSC · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-PCSSC | ACTIVE_COMPARATOR | - |
| Sterile Normal Saline (0.9% NaCl) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALN-PCSSC | DRUG | Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection |
| Sterile Normal Saline (0.9% NaCl) | DRUG | calculated volume to match active comparator |
Inclusion Criteria: * Adequate complete blood counts, liver and renal function * Female subjects must be of non-childbearing potential; e.g. post-menopausal or pre-menopausal with surgical sterilization * Male subjects agree to use appropriate contraception * Willing to provide written informed con...
ALN-PCSSC is an investigational drug being studied for the treatment of hypercholesterolemia, a condition characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C). It is currently in Phase 1 clinical development and has not been approved for any use.
ALN-PCSSC is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALNY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
ALN-PCSSC is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study has been completed to assess its safety and tolerability in subjects with elevated LDL-C.
ALN-PCSSC has one completed Phase 1 clinical trial registered as NCT02314442. This study, titled 'A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C),' enrolled 70 participants in the United Kingdom and included healthy volunteers.
No alternative names for ALN-PCSSC have been reported. The drug is identified solely by its code name ALN-PCSSC in clinical trial registrations and scientific literature. It is distinct from other investigational agents in Alnylam's pipeline.